Expression of NLK and its potential effect in ovarian cancer chemotherapy

International Journal of Gynecological Cancer

Volumn 21, Issue 8, 2011, Pages 1380-1387

  Zhang, Yuquan ^a,b   Peng, Chen ^a,b   Wu, Gang ^b   Wang, You ^c   Liu, Rong ^a   Yang, Shuyun ^a   He, Song ^a   He, Fei ^a   Yuan, Qin ^a   Huang, Yeqing ^a   Shen, Aiguo ^a,b   Cheng, Chun ^a,b  

^a NANTONG UNIVERSITY   (China)

^b NANTONG MEDICAL COLLEGE   (China)

^c Department of Breast Surgery   (China)

Author keywords

Apoptosis; Cisplatin; NLK; Ovarian cancer; Prognosis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CISPLATIN; CYCLIN DEPENDENT KINASE; FORMALDEHYDE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEMO LIKE KINASE; PARAFFIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NLK PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FISHER EXACT TEST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOLOGY; PERITONEAL FLUID; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; CARCINOMA; METABOLISM; OVARY; OVARY TUMOR; PROGNOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84863230462     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182262030     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Rustin GJ, Bast RC Jr, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004;10:3919-3926. (Pubitemid 38697628)
3. Judson PL, Watson JM, Gehrig PA, et al. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res. 1999;59:2425-2432. (Pubitemid 29242292)
4. Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther. 2005;312:424-431. (Pubitemid 40189538)
5. Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 2003;278:19245-19256. (Pubitemid 36799316)
6. Choi KW, Benzer S. Rotation of photoreceptor clusters in the developing Drosophila eye requires the nemo gene. Cell. 1994;78:125-136. (Pubitemid 24228307)
7. Rocheleau CE, Yasuda J, Shin TH, et al. WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in C. elegans. Cell. 1999;97:717-726. (Pubitemid 29278046)
8. Brott BK, Pinsky BA, Erikson RL. Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc Natl Acad Sci U S A. 1998;95:963-968. (Pubitemid 28124895)
9. Ishitani T, Ninomiya-Tsuji J, Nagai S, et al. The TAK1-NLK-MAPK - related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature. 1999;399:798-802. (Pubitemid 29293177)
10. Meneghini MD, Ishitani T, Carter JC, et al. MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans. Nature. 1999;399:793-797. (Pubitemid 29293176)
11. Shin TH, Yasuda J, Rocheleau CE, et al. MOM-4, a MAP kinase kinase kinase - related protein, activates WRM-1/LIT-1 kinase to transduce anterior/posterior polarity signals in C. elegans. Mol Cell. 1999;4:275-280. (Pubitemid 29456896)
12. Ishitani T, Kishida S, Hyodo-Miura J, et al. The TAK1-NLK mitogen - activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol. 2003;23:131-139. (Pubitemid 36008507)
13. Ishitani T, Ninomiya-Tsuji J, Matsumoto K. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase - related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol Cell Biol. 2003;23:1379-1389. (Pubitemid 36177046)
14. Smit L, Baas A, Kuipers J, et al. Wnt activates the Tak1/Nemo-like kinase pathway. J Biol Chem. 2004;279:17232-17240. (Pubitemid 38560481)
15. Thorpe CJ, Moon RT. nemo-like kinase is an essential co-activator of Wnt signaling during early zebrafish development. Development. 2004;131:2899-2909. (Pubitemid 38997278)
16. Yasuda J, Tsuchiya A, Yamada T, et al. Nemo-like kinase induces apoptosis in DLD-1 human colon cancer cells. Biochem Biophys Res Commun. 2003;308:227-233. (Pubitemid 36937170)
17. Yasuda J, Yokoo H, Yamada T, et al. Nemo-like kinase suppresses a wide range of transcription factors, including nuclear factor-kappaB. Cancer Sci. 2004;95:52-57. (Pubitemid 38208407)
18. Ohkawara B, Shirakabe K, Hyodo-Miura J, et al. Role of the TAK1-NLK-STAT3 pathway in TGF-beta-mediated mesoderm induction. Genes Dev. 2004;18:381-386. (Pubitemid 38316345)
19. Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, et al. Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev. 2004;18:816-829. (Pubitemid 38480893)
20. Kurahashi T, Nomura T, Kanei-Ishii C, et al. The Wnt-NLK signaling pathway inhibits A-Myb activity by inhibiting the association with coactivator CBP and methylating histone H3. Mol Biol Cell. 2005;16:4705-4713. (Pubitemid 41416453)
21. Zeng YA, Rahnama M, Wang S, et al. Drosophila Nemo antagonizes BMP signaling by phosphorylation of Mad and inhibition of its nuclear accumulation. Development. 2007;134:2061-2071. (Pubitemid 46979793)
22. Takada I, Mihara M, Suzawa M, et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol. 2007;9:1273-1285. (Pubitemid 350042359)
23. Yamada M, Ohkawara B, Ichimura N, et al. Negative regulation of Wnt signalling by HMG2L1, a novel NLK-binding protein. Genes Cells. 2003;8:677-684. (Pubitemid 36974696)
24. Satoh K, Ohnishi J, Sato A, et al. Nemo-like kinase-myocyte enhancer factor 2A signaling regulates anterior formation in Xenopus development. Mol Cell Biol. 2007;27:7623-7630. (Pubitemid 350033667)
25. Jung KH, Kim JK, Noh JH, et al. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem. 2010;110:687-696.
26. Emami KH, Brown LG, Pitts TE, et al. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate. 2009;69:1481-1492.
27. Ohnishi E, Goto T, Sato A, et al. Nemo-like kinase, an essential effector of anterior formation, functions downstream of p38 mitogen-activated protein kinase. Mol Cell Biol. 2010;30:675-683.
28. Takebe N, Harris PJ, Warren RQ, et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011;8:97-106.
29. Gatcliffe TA, Monk BJ, Planutis K, et al. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer. 2008;18:954-962.
30. Arola J, Salmenkivi K, Liu J, et al. p53 and Ki67 in adrenocortical tumors. Endocr Res. 2000;26:861-865. (Pubitemid 32053112)
31. Mir O, Berveiller P, Ropert S, et al. Use of platinum derivatives during pregnancy. Cancer. 2008;113:3069-3074.
32. Fujiwara K. Can carboplatin replace cisplatin for intraperitoneal use? Int J Gynecol Cancer. 2008;18(suppl 1):29-32. (Pubitemid 351389050)
33. Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 2009;69:2996-3003.